@article{IR,
      recid = {43584},
      author = {Chandra, Daniel and Burns, Faith and Kosaka, Yoko and  Kurtz, Stephen E. and Tyner, Jeffrey W. and Lind, Evan F.  and Saultz, Jennifer N.},
      title = {Upregulation of HLA-e drives defective natural killer cell  targeting in venetoclax-resistant acute myeloid leukemia},
      publisher = {Oregon Health and Science University},
      address = {2024},
      number = {IR},
      abstract = {Acute myeloid leukemia (AML) is the most common leukemia  in adults and is primarily diagnosed in older patients. The  combination of the BCL2 inhibitor, venetoclax, with a  hypomethylating agent has recently become standard of care  front-line therapy for patients who are unfit for high  intensity induction chemotherapy and allogeneic stem cell  transplantation. However, for patients who experience  disease refractoriness/relapse, second line treatment  options are limited. Natural killer (NK) cells have been  shown to have potent anti-tumor effects in AML may  represent a potential therapeutic option for patients with  progression after venetoclax-based therapy.},
      url = {http://digitalcollections.ohsu.edu/record/43584},
      doi = {https://doi.org/10.6083/bpxhc43584},
}